Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all?. Issue 1 (25th July 2017)

• Record Type: Journal Article
• Other Names: Monge S investigator.; Mocroft A investigator.; Sabin A investigator.; Touloumi G investigator.; Sighem A investigator.; Abgrall S investigator.; Dray‐Spira R investigator.; Spire B investigator.; Castagna A investigator.; Mussini C investigator.; Zangerle R investigator.; Hessamfar M investigator.; Anderson J investigator.; Hamouda O investigator.; Ehren K investigator.; Obel N investigator.; Kirk O investigator.; Antinori A investigator.; Girardi E investigator.; Saracino A investigator.; Calmy A investigator.; Wit S investigator.; Wittkop L investigator.; Bucher C investigator.; Montoliu A investigator.; Raben D investigator.; Prins M investigator.; Meyer L investigator.; Chene G investigator.; Burns F investigator.; Amo J investigator.; Judd Ali investigator.; Zangerle Robert investigator.; Touloumi Giota investigator.; Warszawski Josiane investigator.; Meyer Laurence investigator.; Dabis François investigator.; Krause Murielle investigator.; Ghosn Jade investigator.; Leport Catherine investigator.; Wittkop Linda investigator.; Reiss Peter investigator.; Wit Ferdinand investigator.; Prins Maria investigator.; Bucher Heiner investigator.; Gibb Diana investigator.; Fätkenheuer Gerd investigator.; Amo Julia investigator.; Obel Niels investigator.; Thorne Claire investigator.; Mocroft Amanda investigator.; Kirk Ole investigator.; Stephan Christoph investigator.; Pérez‐Hoyos Santiago investigator.; Hamouda Osamah investigator.; Bartmeyer Barbara investigator.; Chkhartishvili Nikoloz investigator.; Noguera‐Julian Antoni investigator.; Antinori Andrea investigator.; Monforte Antonella investigator.; Brockmeyer Norbert investigator.; Prieto Luis investigator.; Conejo Pablo investigator.; Soriano‐Arandes Antoni investigator.; Battegay Manuel investigator.; Kouyos Roger investigator.; Mussini Cristina investigator.; Tookey Pat investigator.; Casabona Jordi investigator.; Miró JoseM investigator.; Castagna Antonella investigator.; Konopnick Deborah investigator.; Goetghebuer Tessa investigator.; Sönnerborg Anders investigator.; Torti Carlo investigator.; Sabin Caroline investigator.; Teira Ramon investigator.; Garrido Myriam investigator.; Haerry David investigator.; Wit Stéphane investigator.; Miró Mª investigator.; Costagliola Dominique investigator.; d'Arminio‐Monforte Antonella investigator.; Castagna Antonella investigator.; Amo Julia investigator.; Mocroft Amanda investigator.; Raben Dorthe investigator.; Chêne Geneviève investigator.; Judd Ali investigator.; Conejo Pablo investigator.; Barger Diana investigator.; Schwimmer Christine investigator.; Termote Monique investigator.; Wittkop Linda investigator.; Campbell Maria investigator.; Frederiksen Casper M investigator.; Friis‐Møller Nina investigator.; Kjaer Jesper investigator.; Raben Dorthe investigator.; Brandt Rikke investigator.; Berenguer Juan investigator.; Bohlius Julia investigator.; Bouteloup Vincent investigator.; Bucher Heiner investigator.; Cozzi‐Lepri Alessandro investigator.; Dabis François investigator.; Monforte Antonella investigator.; Davies Mary‐Anne investigator.; Amo Julia investigator.; Dorrucci Maria investigator.; Dunn David investigator.; Egger Matthias investigator.; Furrer Hansjakob investigator.; Guiguet Marguerite investigator.; Grabar Sophie investigator.; Judd Ali investigator.; Kirk Ole investigator.; Lambotte Olivier investigator.; Leroy Valériane investigator.; Lodi Sara investigator.; Matheron Sophie investigator.; Meyer Laurence investigator.; Miró Jose investigator.; Mocroft Amanda investigator.; Monge Susana investigator.; Nakagawa Fumiyo investigator.; Paredes Roger investigator.; Phillips Andrew investigator.; Puoti Massimo investigator.; Rohner Eliane investigator.; Schomaker Michael investigator.; Smit Colette investigator.; Sterne Jonathan investigator.; Thiebaut Rodolphe investigator.; Thorne Claire investigator.; Torti Carlo investigator.; Valk Marc investigator.; Wittkop Linda investigator.;
• Is Part Of: HIV medicine. Volume 19:Issue 1(2018)
• Page Start: 42
• Page End: 48
• Publication Date: 2017-07-25
• Subjects: HIV -- combination antiretroviral therapy -- immunovirological response -- migrants -- sex; HIV infections -- Treatment -- Periodicals; HIV-positive persons -- Periodicals; HIV infections -- Treatment -- Decision making -- Periodicals; 616.9792
• DOI: 10.1111/hiv.12536
• Languages: English
• ISSNs: 1464-2662

Abstract

Abstract : Objectives: The aim of the study was to evaluate differences in immunovirological response to combination antiretroviral therapy (cART) in migrant and native men and women within a European collaboration of HIV cohorts Collaboration of Observational HIV Epidemiological Research in Europ (COHERE) in EuroCoord, 2004–2013. Methods: Migrants were defined as those with geographical origin (GO) different from the reporting country and were grouped as originating from Western Europe and Western Countries (WEWC), Eastern Europe (EE), North Africa and the Middle East (NAME), sub‐Saharan Africa (SSA), Latin America (LA), Caribbean (CRB) and Asia/Oceania (ASIA/OCE). Native (NAT) individuals were defined as those originating from the reporting country. CD4 cell counts were modelled using piecewise linear mixed‐effects models with two slopes, whereas models to estimate subdistribution hazard ratios (sHRs) were used for time to virological response (VR) (i.e. time from cART initiation to the first of two successive HIV RNA measurements < 400 HIV‐1 RNA copies/ml). Results: Of 32 817 individuals, 25 799 (78.6%) were men. The percentage of migrants was higher in women (48.9%) than in men (21.2%) and migrants from SSA accounted for the largest migrant group (29.9% in men and 63.3% in women). Migrant men and women from SSA started at lower CD4 cell counts than NAT individuals, which remained lower over time. VR was ≥ 85% at 12 months for all groups except CRB women (77.7%). Compared with NAT men and women, lower VR was experienced by NAME [sHR 0.91; 95% confidence interval (CI) 0.86–0.97] and SSA (sHR 0.88; 95% CI 0.82–0.95) men and CRB (sHR 0.77; 85% CI 0.67–0.89) women, respectively. Conclusions: Immunovirological response to cART in Western Europe varies by GO and sex of patients. ART benefits are not equal for all, underlining the point that efforts need to prioritize those most in need.